| Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma | N/A | Melanoma and Skin Cancer Trials Limited | <1 mi |
| Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer | Phase 3 | NRG Oncology | <1 mi |
| Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors | — | SWOG Cancer Research Network | <1 mi |
| MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity | Phase 3 | SWOG Cancer Research Network | <1 mi |
| Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer | Phase 1 | Stanford University | <1 mi |
| A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer | N/A | NRG Oncology | <1 mi |
| Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | Phase 3 | SWOG Cancer Research Network | <1 mi |
| Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) | Phase 2 | SWOG Cancer Research Network | <1 mi |
| Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) | Phase 2/3 | SWOG Cancer Research Network | <1 mi |
| A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia | N/A | University of Colorado, Denver | <1 mi |
| E-Mindfulness Approaches for Living After Breast Cancer | Phase 3 | NRG Oncology | <1 mi |
| mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) | Phase 3 | NRG Oncology | <1 mi |
| Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | Phase 3 | SWOG Cancer Research Network | <1 mi |
| Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer | Phase 3 | NRG Oncology | <1 mi |
| Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response | Phase 3 | Canadian Cancer Trials Group | <1 mi |
| Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease | Phase 2/3 | NRG Oncology | <1 mi |
| Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer | Phase 2 | American Society of Clinical Oncology | <1 mi |
| Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer | Phase 2/3 | NRG Oncology | <1 mi |
| Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas | Phase 2 | Alliance for Clinical Trials in Oncology | <1 mi |
| Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment | Phase 3 | Canadian Cancer Trials Group | <1 mi |
| Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers | Phase 2 | NRG Oncology | <1 mi |
| Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer | Phase 2/3 | SWOG Cancer Research Network | <1 mi |
| Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics | — | Wake Forest University Health Sciences | <1 mi |
| High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 | Phase 3 | NRG Oncology | <1 mi |
| Distance-Based Exercise to Preserve Function and Prevent Disability | N/A | Alliance for Clinical Trials in Oncology | <1 mi |
| Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer | — | Convergent Genomics, Inc. | <1 mi |
| Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer | N/A | Stanford University | 3 mi |
| Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases | Phase 3 | Canadian Cancer Trials Group | 4 mi |
| Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors | Phase 3 | Children's Oncology Group | 4 mi |
| A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Janssen Research & Development, LLC | 4 mi |
| A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Phase 3 | BeOne Medicines | 4 mi |
| Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer | Phase 3 | Summit Therapeutics | 4 mi |
| Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | 4 mi |
| Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery | Phase 3 | NRG Oncology | 4 mi |
| Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) | Phase 3 | Merck Sharp & Dohme LLC | 4 mi |
| A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma | Phase 1/2 | Hoffmann-La Roche | 4 mi |
| Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | 4 mi |
| A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) | Phase 3 | Eli Lilly and Company | 4 mi |
| Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial | Phase 3 | NRG Oncology | 9 mi |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 | Phase 3 | Summit Therapeutics | 9 mi |
| Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer | Phase 2/3 | National Cancer Institute (NCI) | 9 mi |
| Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | Phase 3 | National Cancer Institute (NCI) | 9 mi |
| Galleri® in the Medicare Population. | N/A | GRAIL, Inc. | 9 mi |
| APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | Phase 2 | National Cancer Institute (NCI) | 9 mi |
| Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer | Phase 3 | Alliance for Clinical Trials in Oncology | 9 mi |
| Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer | Phase 3 | NRG Oncology | 9 mi |
| Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial) | Phase 2 | SWOG Cancer Research Network | 9 mi |
| Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) | Phase 2 | SWOG Cancer Research Network | 9 mi |
| Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial | Phase 3 | SWOG Cancer Research Network | 9 mi |
| A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer | Phase 3 | Hoffmann-La Roche | 9 mi |
| Prevention of Cervical Cancer Using the Genotyping Screening and Same-day Self-sampling | — | Atila Biosystems Inc. | 9 mi |
| Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer | Phase 3 | NRG Oncology | 9 mi |
| Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial | Phase 3 | ECOG-ACRIN Cancer Research Group | 9 mi |
| Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | Phase 3 | National Cancer Institute (NCI) | 9 mi |
| Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer | Phase 3 | Pfizer | 9 mi |
| Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations | Phase 3 | SWOG Cancer Research Network | 9 mi |
| Sacral Neuromodulation for Male Overactive Bladder (MOAB) | N/A | Axonics, Inc. | 11 mi |
| A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) | Phase 3 | Merck Sharp & Dohme LLC | 11 mi |
| Phase IIIb Study of Ribociclib + ET in Early Breast Cancer | Phase 3 | Novartis Pharmaceuticals | 11 mi |
| xPedite: A Study to Expedite DIPG and DMG Research | — | xCures | 13 mi |
| Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects | — | Alliance for Clinical Trials in Oncology | 16 mi |
| A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence | Phase 3 | Stemline Therapeutics, Inc. | 16 mi |
| Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial | Phase 3 | University of Rochester | 16 mi |
| Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp | Phase 3 | Sun Pharmaceutical Industries, Inc. | 16 mi |
| Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities | Phase 3 | Sun Pharmaceutical Industries, Inc. | 16 mi |
| Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer | Phase 3 | ECOG-ACRIN Cancer Research Group | 16 mi |
| Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) | Phase 3 | Daiichi Sankyo | 16 mi |
| Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI | N/A | VA Office of Research and Development | 16 mi |
| Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy | — | Stanford University | 16 mi |
| Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer | Phase 3 | GOG Foundation | 16 mi |
| Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer | Phase 3 | Eli Lilly and Company | 16 mi |
| A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma | Phase 2 | Children's Oncology Group | 16 mi |
| A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome | Phase 1 | BlossomHill Therapeutics | 16 mi |
| Neoadjuvant Darovasertib in Primary Uveal Melanoma | Phase 3 | IDEAYA Biosciences | 16 mi |
| Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors | Phase 1 | Stanford University | 16 mi |
| TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas | Phase 1 | Treeline Biosciences, Inc. | 16 mi |
| ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome | — | Stanford University | 16 mi |
| Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated With Radiation Therapy | — | Massachusetts General Hospital | 16 mi |
| A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1 | Phase 2 | Healx Limited | 16 mi |
| Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1 | Phase 2 | University of Alabama at Birmingham | 16 mi |
| Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma | Phase 1 | Ono Pharmaceutical Co., Ltd. | 16 mi |
| A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT | Phase 2 | Children's Oncology Group | 16 mi |
| Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma | Phase 1/2 | Jazz Pharmaceuticals | 16 mi |
| A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias | Phase 1 | Crossbow Therapeutics, Inc. | 16 mi |
| Pediatric PET/MR Image Registry | — | Stanford University | 16 mi |
| Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study | Phase 3 | National Cancer Institute (NCI) | 16 mi |
| Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity | Phase 1/2 | Jessie L. Alexander | 16 mi |
| Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma | Phase 3 | AstraZeneca | 16 mi |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | Phase 1/2 | Children's Oncology Group | 16 mi |
| Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma | Phase 1/2 | St. Jude Children's Research Hospital | 16 mi |
| GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults | Phase 1 | Stanford University | 16 mi |
| A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab | — | City of Hope Medical Center | 16 mi |
| REGULUS: MRI-guided Adaptive SABR for Liver Cancers | Phase 2 | Stanford University | 16 mi |
| A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) | Phase 1 | Kura Oncology, Inc. | 16 mi |
| Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) | Phase 3 | Children's Oncology Group | 16 mi |
| Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects | Phase 3 | Greenwich LifeSciences, Inc. | 16 mi |
| SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) | Phase 3 | Nuvation Bio Inc. | 16 mi |
| Comparing SingLe- Vs Multi-Fraction Spine STereotActic Radiosurgery in Spinal Metastases | Phase 3 | Stanford University | 16 mi |
| Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment | Phase 3 | National Cancer Institute (NCI) | 16 mi |
| AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | Phase 2 | AstraZeneca | 16 mi |
| Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers | Phase 2 | Corcept Therapeutics | 16 mi |
| Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study | — | M.D. Anderson Cancer Center | 16 mi |
| A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms | Phase 1 | Incyte Corporation | 16 mi |
| TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II | Phase 1/2 | Tanja Andrea Gruber | 16 mi |
| A Study to Give Treatment Inside the Eye to Treat Retinoblastoma | Phase 2 | Children's Oncology Group | 16 mi |
| Intra-procedural Spectral CT for Image-guided Embolization and Ablation in Interventional Oncology | — | Palo Alto Veterans Institute for Research | 16 mi |
| Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy | Phase 3 | Children's Oncology Group | 16 mi |
| A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 2 | National Cancer Institute (NCI) | 16 mi |
| CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. | Phase 2 | TORL Biotherapeutics, LLC | 16 mi |
| A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) | Phase 1/2 | Nuvalent Inc. | 16 mi |
| Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study | Phase 2 | Darcy Krueger | 16 mi |
| A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer | Phase 2 | VA Office of Research and Development | 16 mi |
| Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors | Phase 1 | Exelixis | 16 mi |
| A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma | Phase 2/3 | Replimune, Inc. | 16 mi |
| Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy | Phase 2/3 | Novartis Pharmaceuticals | 16 mi |
| Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers | Phase 1 | Novartis Pharmaceuticals | 16 mi |
| A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study | Phase 1 | Novartis Pharmaceuticals | 16 mi |
| Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 3 | Revolution Medicines, Inc. | 16 mi |
| A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies | Phase 1/2 | BeOne Medicines | 16 mi |
| A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) | Phase 3 | Merck Sharp & Dohme LLC | 16 mi |
| Umbilical Vessel Catheterization Under ECG Monitoring and Guidance | N/A | Stanford University | 16 mi |
| Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery | Phase 1/2 | Stanford University | 16 mi |
| A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | Phase 3 | Loxo Oncology, Inc. | 16 mi |
| Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer | Phase 2 | National Cancer Institute (NCI) | 16 mi |
| A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms | Phase 1 | Incyte Corporation | 16 mi |
| ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer | Phase 3 | BioNTech SE | 16 mi |
| iMOVE: Virtual Reality PT Versus Traditional PT | N/A | Stanford University | 16 mi |
| A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT | Phase 2 | Children's Oncology Group | 16 mi |
| Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy | Phase 3 | RayzeBio, Inc. | 16 mi |
| A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | Phase 1 | Incyte Corporation | 16 mi |
| Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. | Phase 2/3 | Novartis Pharmaceuticals | 16 mi |
| Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases | Phase 2 | Stanford University | 16 mi |
| Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1) | Phase 1 | Ichnos Sciences SA | 16 mi |
| A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) | Phase 3 | BeOne Medicines | 16 mi |
| A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors | Phase 2 | Georgetown University | 16 mi |
| Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors | Phase 1 | Xencor, Inc. | 16 mi |
| Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer | Phase 3 | Relay Therapeutics, Inc. | 16 mi |
| A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC) | — | Tempus AI | 16 mi |
| Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment | — | Children's Oncology Group | 16 mi |
| A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan | Phase 2 | AbbVie | 16 mi |
| Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback | Phase 1 | Porteus, Matthew, MD | 16 mi |
| Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia | Phase 1/2 | Aptose Biosciences Inc. | 16 mi |
| Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer | Phase 1 | Astellas Pharma Global Development, Inc. | 16 mi |
| Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer | Phase 1/2 | Teclison Ltd. | 16 mi |
| Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML | Phase 1/2 | Stanford University | 16 mi |
| A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation | Phase 2 | Center for International Blood and Marrow Transplant Research | 16 mi |
| Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients | Phase 1 | Fox Chase Cancer Center | 16 mi |
| Project: Every Child for Younger Patients With Cancer | — | Children's Oncology Group | 16 mi |
| Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC) | Phase 2 | Stanford University | 16 mi |
| Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL) | — | St. Jude Children's Research Hospital | 16 mi |
| Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO | Phase 1 | National Cancer Institute (NCI) | 16 mi |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types | Phase 1/2 | Eisai Inc. | 16 mi |
| Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors | Phase 1/2 | Tango Therapeutics, Inc. | 16 mi |
| Multidimensional and Multimodal Profiling of Oropharyngeal Carcinoma | — | Stanford University | 16 mi |
| EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma | Phase 3 | NovoCure GmbH | 16 mi |
| A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) | Phase 3 | Merck Sharp & Dohme LLC | 16 mi |
| Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease | Phase 2 | St. Jude Children's Research Hospital | 16 mi |
| Digital Phenotyping for Psychosocial Screening in Adolescents and Young Adults With Cancer | N/A | Stanford University | 16 mi |
| Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours | Phase 3 | University of Sydney | 16 mi |
| A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of the Dayspring Technology for Patients With Breast Cancer Related Lymphedema (BCRL) After Lymphatic Surgery | N/A | Koya Medical, Inc. | 16 mi |
| A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma | Phase 1 | Kelonia Therapeutics, Inc. | 16 mi |
| A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) | Phase 3 | AstraZeneca | 16 mi |
| Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma | Phase 3 | Children's Oncology Group | 16 mi |
| DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer | Phase 3 | AstraZeneca | 16 mi |
| Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors | Phase 1 | Riboscience, LLC. | 16 mi |
| Neuroblastoma Biology Study | — | New Approaches to Neuroblastoma Therapy Consortium | 16 mi |
| A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer | Phase 3 | Eli Lilly and Company | 16 mi |
| A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis | Phase 2/3 | Janssen Research & Development, LLC | 16 mi |
| Phase II Trial Comparison of 3 vs 4 Fractions (BRACHY-FIT). | Phase 2 | Stanford University | 16 mi |
| Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body | — | Bayer | 16 mi |
| AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia | Phase 1/2 | AstraZeneca | 16 mi |
| A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors | Phase 2 | Memorial Sloan Kettering Cancer Center | 16 mi |
| A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | Phase 3 | AstraZeneca | 16 mi |
| FOG-001 in Locally Advanced or Metastatic Solid Tumors | Phase 1/2 | Parabilis Medicines, Inc. | 16 mi |
| A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases | Phase 1 | Arcellx, Inc. | 16 mi |
| Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC | Phase 3 | Novartis Pharmaceuticals | 16 mi |
| Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors | — | Stanford University | 16 mi |
| Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma | Phase 3 | National Cancer Institute (NCI) | 16 mi |
| Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors | Phase 1 | Stanford University | 16 mi |
| Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors | Phase 2/3 | Exelixis | 16 mi |
| Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy | — | Adaptive Biotechnologies | 16 mi |
| Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery | Phase 1/2 | Stanford University | 16 mi |
| A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations | Phase 3 | Children's Oncology Group | 16 mi |
| Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) | Phase 3 | Merck Sharp & Dohme LLC | 16 mi |
| A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors | Phase 1 | Peel Therapeutics Inc | 16 mi |
| Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel | Phase 1 | Stanford University | 16 mi |
| A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) | Phase 1/2 | National Cancer Institute (NCI) | 16 mi |
| Interventions in Mathematics and Cognitive Skills | N/A | Stanford University | 16 mi |
| An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. | Phase 3 | Novartis Pharmaceuticals | 16 mi |
| A Study of CTD402 in T-ALL/LBL Patients | Phase 1/2 | Imviva Bio | 16 mi |
| A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer | N/A | GOG Foundation | 16 mi |
| KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis | Phase 2/3 | Kyverna Therapeutics | 16 mi |
| A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation | Phase 1/2 | D3 Bio (Wuxi) Co., Ltd | 16 mi |
| A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) | Phase 3 | Children's Oncology Group | 16 mi |
| AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas | Phase 1 | Stanford University | 16 mi |
| Development of 3D Multi-Parametric Ultrasound (MPUS) as a Decision Support Tool for Patients | — | University of California, San Diego | 16 mi |
| Niclosamide in Pediatric Patients With Relapsed and Refractory AML | Phase 1 | Stanford University | 16 mi |
| A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Loxo Oncology, Inc. | 16 mi |
| Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging | Phase 3 | ECOG-ACRIN Cancer Research Group | 16 mi |
| Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors | Phase 1 | Gilead Sciences | 16 mi |
| Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas | Phase 3 | Matthew Bucknor | 16 mi |
| Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer | Phase 3 | University of Utah | 16 mi |
| Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma | Phase 1/2 | Oncorena AB | 16 mi |
| A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 2 | National Cancer Institute (NCI) | 16 mi |
| SPEARHEAD-3 Pediatric Study | Phase 1/2 | USWM CT, LLC | 16 mi |
| A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors | Phase 1/2 | Biohaven Therapeutics Ltd. | 16 mi |
| The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study | Phase 1/2 | PedAL BCU, LLC | 16 mi |
| A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors. | Phase 1 | FoRx Therapeutics AG | 16 mi |
| Study of Cryoablation and Nirogacestat for Desmoid Tumor | Phase 2 | Nam Bui | 16 mi |
| A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) | Phase 1/2 | Sumitomo Pharma America, Inc. | 16 mi |
| Methods of Identifying Effective Off-Guideline Treatments for Advanced Cancer Patients (CC N-of-1) | — | Cancer Commons | 16 mi |
| Prospective Study of oncRNA Stratification of Cancer by Size and Stage | — | Exai Bio Inc. | 16 mi |
| A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation | Phase 1/2 | Syndax Pharmaceuticals | 16 mi |
| 5-Day Preoperative Radiation for Soft Tissue Sarcoma | Phase 2 | Stanford University | 16 mi |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | Phase 2 | National Cancer Institute (NCI) | 16 mi |
| Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90 | — | Palo Alto Veterans Institute for Research | 16 mi |
| Prospective Data Registry and Quality of Life Assessment of Patients Undergoing Radiotherapy With the RefleXion Medical Radiotherapy System | — | RefleXion Medical | 16 mi |
| A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | Hoffmann-La Roche | 16 mi |
| A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma | Phase 2 | Acrivon Therapeutics | 16 mi |
| Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma | Phase 2 | Stanford University | 16 mi |
| Avapritinib With Decitabine in Patients With SM-AHN | Phase 1 | H. Lee Moffitt Cancer Center and Research Institute | 16 mi |
| Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer | Phase 3 | National Cancer Institute (NCI) | 16 mi |
| Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) | Phase 1/2 | Rigel Pharmaceuticals | 16 mi |
| EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD) | — | Exact Sciences Corporation | 16 mi |
| Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma | Phase 3 | Children's Oncology Group | 16 mi |
| A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) | Phase 2 | National Cancer Institute (NCI) | 16 mi |
| (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis | Phase 2/3 | Blueprint Medicines Corporation | 16 mi |
| A Study of PHST001 in Advanced Solid Tumors | Phase 1 | Pheast Therapeutics | 16 mi |
| Blue Light Cystoscopy With Cysview® Registry | — | Photocure | 16 mi |
| Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Phase 2 | Mayo Clinic | 16 mi |
| Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing | — | A2 Biotherapeutics Inc. | 16 mi |
| Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma | Phase 2 | St. Jude Children's Research Hospital | 16 mi |
| Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT | Phase 1 | Stanford University | 16 mi |
| Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery | Phase 1/2 | George Poultsides | 16 mi |
| Suprachoroidal Administration in Subjects With Metastases to the Choroid | Phase 2 | Aura Biosciences | 16 mi |
| A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer | Phase 1/2 | Regeneron Pharmaceuticals | 16 mi |
| A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer | Phase 1 | AstraZeneca | 16 mi |
| Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies | Phase 1 | Stanford University | 16 mi |
| Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy | Phase 2/3 | Bristol-Myers Squibb | 16 mi |
| Molecular and Cellular Profiling of Uterine Lavage Collected During Gynecologic Surgery | N/A | Stanford University | 16 mi |
| Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma | Phase 3 | Arcus Biosciences, Inc. | 16 mi |
| Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) | Phase 3 | Merck Sharp & Dohme LLC | 16 mi |
| A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer | Phase 1 | Stemline Therapeutics, Inc. | 16 mi |
| A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer | Phase 1 | Bristol-Myers Squibb | 16 mi |
| Adolescents and Young Adults With Cancer: Their Preferred Involvement in Decision Making | N/A | Stanford University | 16 mi |
| Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps | N/A | NRG Oncology | 16 mi |
| A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) | Phase 3 | Merus B.V. | 16 mi |
| Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia | Phase 2 | National Cancer Institute (NCI) | 16 mi |
| Engagement of Veterans With Lung Cancer | N/A | Palo Alto Veterans Institute for Research | 16 mi |
| Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity | Phase 2/3 | ECOG-ACRIN Cancer Research Group | 16 mi |
| Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma | Phase 2 | Jazz Pharmaceuticals | 16 mi |
| A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia | Phase 3 | BeOne Medicines | 16 mi |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) | Phase 1/2 | Bristol-Myers Squibb | 16 mi |
| A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis | Phase 3 | Janssen Research & Development, LLC | 16 mi |
| Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC | Phase 1/2 | VA Office of Research and Development | 16 mi |
| A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer | Phase 2 | Hoffmann-La Roche | 16 mi |
| Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT. | N/A | bioAffinity Technologies Inc. | 16 mi |
| Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII | Phase 2 | Black Diamond Therapeutics, Inc. | 16 mi |
| A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer | Phase 1 | Immunome, Inc. | 16 mi |
| A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases | Phase 1 | Kite, A Gilead Company | 16 mi |
| Intraoperative Wound Irrigation for Pilonidal Disease | N/A | Stanford University | 16 mi |
| A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) | Phase 1 | AbbVie | 16 mi |
| Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor | Phase 2 | National Cancer Institute (NCI) | 16 mi |
| A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer | Phase 3 | AstraZeneca | 16 mi |
| Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial | Phase 3 | National Cancer Institute (NCI) | 16 mi |
| TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT | Phase 1 | Stanford University | 16 mi |
| Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases. | Phase 2 | Stanford University | 16 mi |
| Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation | Phase 1 | Laguna Biotherapeutics, Inc. | 16 mi |
| Advocacy, Partnership, Outreach, and Yielding Optimized Care for Oncology Patients | N/A | Stanford University | 16 mi |
| A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies | Phase 1/2 | Ellipses Pharma | 17 mi |
| (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis | Phase 2 | Cogent Biosciences, Inc. | 17 mi |
| A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression | Phase 1/2 | A2 Biotherapeutics Inc. | 17 mi |
| Bio-Repository of High Risk Cohorts for the Early Detection of Pancreas Cancer | — | Stanford University | 17 mi |
| A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) | Phase 1 | Solu Therapeutics, Inc | 17 mi |
| FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC | Phase 2/3 | Bicara Therapeutics | 17 mi |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | Phase 1/2 | Hoffmann-La Roche | 17 mi |
| ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors | Phase 1/2 | Immatics US, Inc. | 17 mi |
| Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease | — | Stanford University | 17 mi |
| A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors | Phase 1 | D3 Bio (Wuxi) Co., Ltd | 17 mi |
| Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors | Phase 1/2 | Revolution Medicines, Inc. | 17 mi |
| 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE) | Phase 1/2 | Clarity Pharmaceuticals Ltd | 17 mi |
| Safety and Efficacy of OBX-115 in Advanced Solid Tumors | Phase 1/2 | Obsidian Therapeutics, Inc. | 17 mi |
| A Registry for People With T-cell Lymphoma | — | Memorial Sloan Kettering Cancer Center | 17 mi |
| Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy | Phase 3 | Clarity Pharmaceuticals Ltd | 17 mi |
| A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis | Phase 3 | Sumitomo Pharma Switzerland GmbH | 17 mi |
| A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies | Phase 1 | Orca Biosystems, Inc. | 17 mi |
| Safety and Durability of Sirolimus for Treatment of LAM | — | University of Cincinnati | 17 mi |
| Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | Phase 1 | Anusha Kalbasi | 17 mi |
| Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers | — | Stanford University | 17 mi |
| Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors | Phase 1/2 | Alyssum Therapeutics | 17 mi |
| Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer | Phase 2 | EXACT Therapeutics AS | 17 mi |
| A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma | Phase 1 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 17 mi |
| A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) | Phase 2/3 | Bristol-Myers Squibb | 17 mi |
| Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD) | Phase 2 | Jennifer Amengual | 17 mi |
| A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma | Phase 2/3 | Linnaeus Therapeutics, Inc. | 17 mi |
| BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL | Phase 1 | PeproMene Bio, Inc. | 17 mi |
| Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures | Phase 1/2 | Stanford University | 17 mi |
| Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC | Phase 3 | Maximilian Diehn | 17 mi |
| Fabry Disease Registry & Pregnancy Sub-registry | — | Genzyme, a Sanofi Company | 17 mi |
| ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) | Phase 3 | Jazz Pharmaceuticals | 17 mi |
| A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma | Phase 2/3 | Global Coalition for Adaptive Research | 17 mi |
| Magnetic Resonance Imaging of Breast Cancer | N/A | Stanford University | 17 mi |
| Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers | N/A | City of Hope Medical Center | 17 mi |
| Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer | Phase 1/2 | Heike E Daldrup-Link | 17 mi |
| Aromatherapy Inhaler Use for HSCT Distress | N/A | Stanford University | 17 mi |
| Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas | Phase 1 | City of Hope Medical Center | 17 mi |
| DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma | Phase 2 | Giselle Sholler | 17 mi |
| International REgistry of COnservative or Radical Treatment of Localized Kidney Tumors | — | Azienda Ospedaliero-Universitaria Careggi | 17 mi |
| Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy | — | Stanford University | 17 mi |
| A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | Phase 4 | Janssen Research & Development, LLC | 17 mi |
| Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia | N/A | Massachusetts General Hospital | 17 mi |
| Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy | Phase 2 | Beth Israel Deaconess Medical Center | 17 mi |
| Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy | Phase 1 | Norman J. Lacayo | 17 mi |
| Post-Exablate Pregnancy Outcomes Registry Study: Exablate Treatment of Symptomatic Uterine Fibroids | — | InSightec | 17 mi |
| Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome | Phase 2 | Stanford University | 17 mi |
| Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma | Phase 2 | Memorial Sloan Kettering Cancer Center | 17 mi |
| Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma | N/A | Stanford University | 17 mi |
| A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors | Phase 1/2 | Bayer | 17 mi |
| Childhood Cancer Survivor Study | — | St. Jude Children's Research Hospital | 17 mi |
| Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients | Phase 2 | Memorial Sloan Kettering Cancer Center | 17 mi |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer | Phase 1/2 | Hoffmann-La Roche | 17 mi |
| Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma | — | Stanford University | 17 mi |
| Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities | Phase 1/2 | Taiho Pharmaceutical Co., Ltd. | 17 mi |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | — | Massive Bio, Inc. | 17 mi |
| Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies | Phase 1 | BioEclipse Therapeutics | 17 mi |
| A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) | Phase 1/2 | Nuvalent Inc. | 17 mi |
| Measuring Surgical Recovery After Radical Cystectomy | — | M.D. Anderson Cancer Center | 17 mi |
| Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer | Phase 1 | VLP Therapeutics | 17 mi |
| A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials | Phase 3 | Celgene | 17 mi |
| Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma | Phase 2/3 | TuHURA Biosciences, Inc. | 17 mi |
| A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer | Phase 2 | Janssen Research & Development, LLC | 17 mi |
| Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled Trial | N/A | Tobias Todsen | 17 mi |
| Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma. | — | Associazione Angela Serra per la ricerca sul cancro | 17 mi |
| A Long-term Extension Study of PCI-32765 (Ibrutinib) | Phase 3 | Janssen Research & Development, LLC | 17 mi |
| A Study of LY4175408 in Participants With Advanced Cancer | Phase 1 | Eli Lilly and Company | 17 mi |
| DALY II USA/ MB-CART2019.1 for DLBCL | Phase 2 | Miltenyi Biomedicine GmbH | 17 mi |
| The Gastric Cancer Foundation: A Gastric Cancer Registry | — | Stanford University | 17 mi |
| Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements | Phase 1/2 | Joshua Palmer | 17 mi |
| A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC) | Phase 1/2 | BioNTech SE | 17 mi |
| A Study of LY4257496 in Participants With Cancer (OMNIRAY) | Phase 1 | Eli Lilly and Company | 17 mi |
| Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma | Phase 1 | Opna Bio LLC | 17 mi |
| International Pediatric Adrenocortical Tumor Registry | — | St. Jude Children's Research Hospital | 17 mi |
| Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer. | Phase 3 | SOFIE | 17 mi |
| A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD) | Phase 1 | GlaxoSmithKline | 17 mi |
| Brentuximab Vedotin in Early Stage Hodgkin Lymphoma | Phase 3 | University College, London | 17 mi |
| SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma | Phase 3 | Immatics US, Inc. | 17 mi |
| Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | 17 mi |
| 99mTc Sestamibi SPECT/CT vs 18F Fluorocholine PET/CT | Phase 2/3 | Andrei Iagaru | 17 mi |
| Impact of the Coronavirus (COVID-19) on Patients With Cancer | — | Stanford University | 17 mi |
| A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations | Phase 1/2 | BlossomHill Therapeutics | 17 mi |
| Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU | — | Miltenyi Biomedicine GmbH | 17 mi |
| Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC | Phase 1/2 | Revolution Medicines, Inc. | 17 mi |
| Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations | Phase 1 | Tyra Biosciences, Inc | 17 mi |
| 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer | Phase 1/2 | Lantheus Medical Imaging | 17 mi |
| Evaluation of Grief Therapy Approaches for Bereaved Parents | N/A | University of Miami | 17 mi |
| A Study of LY4337713 in Participants With FAP-Positive Solid Tumors | Phase 1 | Eli Lilly and Company | 17 mi |
| A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) | Phase 1 | Hoffmann-La Roche | 17 mi |
| Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples | — | Stanford University | 17 mi |
| A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) | — | Center for International Blood and Marrow Transplant Research | 17 mi |
| FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3 | Phase 1 | Eli Lilly and Company | 17 mi |
| A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia | Phase 2 | Memorial Sloan Kettering Cancer Center | 17 mi |
| Prostate Active Surveillance Study | — | University of Washington | 17 mi |
| Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer | Phase 2 | Stanford University | 17 mi |
| Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells | Phase 2/3 | Celgene | 17 mi |
| Study With [225Ac]Ac-FL-020 in mCRPC Participants | Phase 1 | Full-Life Technologies UK Limited | 17 mi |
| A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer | Phase 3 | Janssen Research & Development, LLC | 17 mi |
| Identification and Characterization of Novel Proteins and Genes in Head and Neck Cancer | — | Stanford University | 17 mi |
| Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions | — | Ohio State University Comprehensive Cancer Center | 17 mi |
| A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1) | Phase 1 | Nuvalent Inc. | 17 mi |
| The GAstric Precancerous Conditions Study | — | Stanford University | 17 mi |
| Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) | Phase 3 | Advenchen Laboratories, LLC | 17 mi |
| SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma | Phase 2 | Sarcoma Alliance for Research through Collaboration | 17 mi |
| Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia | Phase 3 | Quetzal Therapeutics | 17 mi |
| Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC | Phase 2 | Pfizer | 17 mi |
| A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma | Phase 1/2 | TORL Biotherapeutics, LLC | 17 mi |
| A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors | Phase 1 | Eli Lilly and Company | 17 mi |
| A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma | Phase 1 | Kyowa Kirin, Inc. | 17 mi |
| Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin | Phase 2 | Stanford University | 22 mi |
| A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas | Phase 1/2 | Dren Bio | 22 mi |
| Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma | Phase 3 | Regeneron Pharmaceuticals | 22 mi |
| ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation | — | Guardant Health, Inc. | 22 mi |
| National Liver Cancer Screening Trial | Phase 4 | University of Texas Southwestern Medical Center | 22 mi |
| The Vanguard Study: Testing a New Way to Screen for Cancer | N/A | National Cancer Institute (NCI) | 22 mi |
| Understanding New Cachexia Subtypes Through Observational Epidemiological Research | — | Kaiser Permanente | 22 mi |
| Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease | Phase 2 | Memorial Sloan Kettering Cancer Center | 24 mi |
| Investigations of Reproductive Cancers in Women | — | PinkDx, Inc. | 24 mi |
| Researching the Effect of Exercise on Cancer | N/A | City of Hope Medical Center | 24 mi |
| Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | — | Alliance for Clinical Trials in Oncology | 25 mi |
| Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma | Phase 3 | ECOG-ACRIN Cancer Research Group | 25 mi |
| Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | Phase 2 | National Cancer Institute (NCI) | 25 mi |
| A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases | Phase 2 | SWOG Cancer Research Network | 25 mi |
| S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer | N/A | SWOG Cancer Research Network | 25 mi |
| Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors | Phase 2 | SWOG Cancer Research Network | 25 mi |
| Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles) | — | GT Medical Technologies, Inc. | 27 mi |
| The PREDICT Registry: | — | PreludeDx | 29 mi |
| Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial | Phase 2 | NRG Oncology | 29 mi |
| Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | 29 mi |
| Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Phase 3 | Pfizer | 38 mi |
| A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning | N/A | Ricoh USA, Inc. | 39 mi |
| A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients | Phase 3 | Children's Oncology Group | 39 mi |
| The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL | Phase 2 | Pediatric Transplantation & Cellular Therapy Consortium | 39 mi |
| Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer | Phase 3 | Children's Oncology Group | 39 mi |
| A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) | Phase 2 | National Cancer Institute (NCI) | 39 mi |
| Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance | N/A | University of Colorado, Denver | 39 mi |
| Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer | Phase 2 | AstraZeneca | 39 mi |
| Pediatric Precision Laboratory Advanced Neuroblastoma Therapy | Phase 2 | Giselle Sholler | 39 mi |
| A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss | Phase 3 | Children's Oncology Group | 39 mi |
| A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study | Phase 2 | Children's Oncology Group | 39 mi |
| A Study of Shengbai Oral Formula to Assess Safety and Alleviation of Adverse Effects in Cancer Patients Undergoing Chemotherapy | N/A | Sutter Health | 39 mi |
| Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer | N/A | AdventHealth Translational Research Institute | 39 mi |
| TSC Biosample Repository and Natural History Database | — | National Tuberous Sclerosis Association | 39 mi |
| Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma | Phase 2 | Giselle Sholler | 39 mi |
| Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia | Phase 2 | National Cancer Institute (NCI) | 39 mi |
| Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors | Phase 1/2 | Milton S. Hershey Medical Center | 39 mi |
| Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma | Phase 3 | Children's Oncology Group | 39 mi |
| A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202) | Phase 3 | Bristol-Myers Squibb | 39 mi |
| Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer | Phase 3 | Pharmacosmos A/S | 39 mi |
| Quality of End-of-Life Care for Children With Cancer | — | Children's Oncology Group | 39 mi |
| Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia | Phase 3 | Children's Oncology Group | 39 mi |
| A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS) | Phase 3 | Children's Oncology Group | 39 mi |
| A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information | N/A | Children's Oncology Group | 39 mi |
| Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer | — | N-Power Medicine | 41 mi |
| A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) | Phase 3 | Merck Sharp & Dohme LLC | 41 mi |
| A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer | Phase 2 | Eli Lilly and Company | 41 mi |
| A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) | Phase 3 | Merck Sharp & Dohme LLC | 41 mi |
| Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations | — | Blueprint Medicines Corporation | 41 mi |
| Observational Study Protocol: LIVER-R | — | AstraZeneca | 41 mi |
| A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) | Phase 3 | Pfizer | 41 mi |
| Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers | N/A | University of California, San Francisco | 41 mi |
| Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer | Phase 3 | AstraZeneca | 41 mi |
| DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment | Phase 2 | QuantumLeap Healthcare Collaborative | 41 mi |
| A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) | Phase 2 | Merck Sharp & Dohme LLC | 41 mi |
| Colonoscopy vs Stool Testing for Older Adults With Colon Polyps | N/A | Dartmouth-Hitchcock Medical Center | 41 mi |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC | Phase 3 | AstraZeneca | 41 mi |
| Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer | Phase 3 | AstraZeneca | 41 mi |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) | Phase 3 | AstraZeneca | 41 mi |
| A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) | Phase 2/3 | Merck Sharp & Dohme LLC | 41 mi |
| A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | Phase 3 | Eli Lilly and Company | 41 mi |
| Urine Metabolites in the Diagnosis of Disease | — | Luventix, Inc. | 41 mi |
| Collection of Samples USOPTIVAL Study | — | Universal Diagnostics | 41 mi |
| A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer | Phase 3 | AstraZeneca | 41 mi |
| Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 | Phase 3 | AstraZeneca | 41 mi |
| A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) | Phase 3 | Merck Sharp & Dohme LLC | 41 mi |
| Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy | Phase 3 | Eastern Cooperative Oncology Group | 41 mi |
| Mechanisms of Resistance to PSMA Radioligand Therapy | — | University of California, San Francisco | 42 mi |
| Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma | Phase 3 | Corvus Pharmaceuticals, Inc. | 42 mi |
| Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma | Phase 2 | University of California, San Diego | 42 mi |
| Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma | Phase 1 | New York Medical College | 42 mi |
| UCSF PANC Cyst Registry | — | University of California, San Francisco | 42 mi |
| A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) | Phase 3 | Merck Sharp & Dohme LLC | 42 mi |
| A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation | Phase 1 | Clasp Therapeutics, Inc. | 42 mi |
| A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | Phase 3 | Jazz Pharmaceuticals | 42 mi |
| Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer | Phase 2 | Syntrix Biosystems, Inc. | 42 mi |
| Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration | Phase 1/2 | ORIC Pharmaceuticals | 42 mi |
| Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study) | — | HistoSonics, Inc. | 42 mi |
| A Novel Multiplex ELISA Assay for Surveilling Patients With History of Bladder Cancer | — | Cedars-Sinai Medical Center | 42 mi |
| ATEMPT 2.0: Adjuvant T-DM1 vs TH | Phase 2 | Dana-Farber Cancer Institute | 42 mi |
| A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas | Phase 1 | EvolveImmune United, Inc | 42 mi |
| 64Cu-GRIP B in Patients With Advanced Malignancies | Phase 1/2 | Rahul Aggarwal | 42 mi |
| AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1) | Phase 1/2 | AstraZeneca | 42 mi |
| Primary Tumor Research and Outcomes Network | — | AO Innovation Translation Center | 42 mi |
| Community-Based Health Coach for Access to Germline Genetic Testing Among African American Men With Prostate Cancer | N/A | University of California, San Francisco | 42 mi |
| Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma | N/A | University of California, San Francisco | 42 mi |
| First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors | Phase 1/2 | Eli Lilly and Company | 42 mi |
| A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001) | Phase 1 | K36 Therapeutics, Inc. | 42 mi |
| Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer | Early 1 | Ivan de Kouchkovsky, MD | 42 mi |
| A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) | Phase 3 | Merck Sharp & Dohme LLC | 42 mi |
| A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma | Phase 1 | K36 Therapeutics, Inc. | 42 mi |
| Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm | — | Thomas Hope | 42 mi |
| Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA) | — | University of California, San Francisco | 42 mi |
| A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer | Phase 3 | Amgen | 42 mi |
| A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | Phase 1 | Nurix Therapeutics, Inc. | 42 mi |
| Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors | Phase 2 | University of California, San Francisco | 42 mi |
| ART-Pro: Clinical Trial Evaluating Biparametric MRI and Advanced, Quantitative Diffusion MRI for Detection of Prostate Cancer | — | University of California, San Diego | 42 mi |
| Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | Phase 1 | Therapeutic Advances in Childhood Leukemia Consortium | 42 mi |
| Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma | N/A | University of California, San Francisco | 42 mi |
| Collecting Blood and Stool Samples to Detect Colorectal Cancer or Advanced Neoplasia in Lynch Syndrome Patients | — | Mayo Clinic | 42 mi |
| A Study of DM002 in Patients With Advanced Solid Tumors | Phase 1/2 | Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | 42 mi |
| Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma | Phase 1 | Alfred Chung, MD | 42 mi |
| Fatigue and Molecular Mechanisms in Cancer Patients Receiving CCRT | — | University of California, San Francisco | 42 mi |
| A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis | Phase 1 | Janssen Research & Development, LLC | 42 mi |
| DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers | Phase 2 | Boehringer Ingelheim | 42 mi |
| ACTengine® IMA203 Combined With mRNA-4203 | Phase 1 | Immatics US, Inc. | 42 mi |
| Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study | — | University of Washington | 42 mi |
| A Study of NX-1607 in Adults With Advanced Malignancies | Phase 1 | Nurix Therapeutics, Inc. | 42 mi |
| A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Hoffmann-La Roche | 42 mi |
| Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer | — | Massachusetts General Hospital | 42 mi |
| Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors | Phase 1 | ITM Solucin GmbH | 42 mi |
| Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma | Phase 1/2 | Remix Therapeutics | 42 mi |
| A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors | Phase 1/2 | AstraZeneca | 42 mi |
| MCT for the Harvard/UCSF ROBIN Center | N/A | Brigham and Women's Hospital | 42 mi |
| Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma | Phase 2 | University of California, San Francisco | 42 mi |
| A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors | Phase 1 | ArriVent BioPharma, Inc. | 42 mi |
| First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. | Phase 1/2 | Corbus Pharmaceuticals Inc. | 42 mi |
| CONNECTing to LungCare | N/A | University of California, San Francisco | 42 mi |
| A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma | Phase 3 | Janssen Research & Development, LLC | 42 mi |
| PediRISE Feasibility | N/A | Dana-Farber Cancer Institute | 42 mi |
| Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Phase 2 | University of Alabama at Birmingham | 42 mi |
| A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012) | Phase 2 | Merck Sharp & Dohme LLC | 42 mi |
| Trial of Ixazomib for Kaposi Sarcoma | Phase 2 | AIDS Malignancy Consortium | 42 mi |
| LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy | N/A | Stanford University | 42 mi |
| Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss | Phase 1/2 | Tango Therapeutics, Inc. | 42 mi |
| DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma | Phase 1/2 | University of California, San Francisco | 42 mi |
| Hyperpolarized Imaging in Diagnosing Participants With Glioma | Phase 1 | Susan Chang | 42 mi |
| Treatment of Radiation and Cisplatin Induced Toxicities with Tempol | Phase 2 | Matrix Biomed, Inc. | 42 mi |
| Ivonescimab for the Treatment of Thymic Cancer | Phase 2 | Jonsson Comprehensive Cancer Center | 42 mi |
| A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors | Phase 1/2 | Corbus Pharmaceuticals Inc. | 42 mi |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer | Phase 2/3 | Bristol-Myers Squibb | 42 mi |
| Mirai-MRI: Validation of AI Models for Breast Cancer Risk | N/A | University of California, San Francisco | 42 mi |
| Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts | — | Mayo Clinic | 42 mi |
| ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Zenith Epigenetics | 42 mi |
| A Study of IBI363 in Subjects with Advanced Solid Malignancies | Phase 2 | Innovent Biologics (Suzhou) Co. Ltd. | 42 mi |
| Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer | Phase 2 | Children's Hospital of Philadelphia | 42 mi |
| Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer | Phase 1 | Amgen | 42 mi |
| MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles | — | Agendia | 42 mi |
| The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma | — | Erasmus Medical Center | 42 mi |
| A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors | Phase 2 | Day One Biopharmaceuticals, Inc. | 42 mi |
| PET [89Zr]DFO-starPEG in Solid Tumors | Phase 1 | Robert Flavell, MD, PhD | 42 mi |
| Screening for AL Amyloidosis in Smoldering Multiple Myeloma | — | Tufts Medical Center | 42 mi |
| PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy | Phase 1 | Michael Randall | 42 mi |
| Smoking Cessation CM for Veterans With or at Risk for Cancer | N/A | VA Office of Research and Development | 42 mi |
| A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations | Phase 2 | Fore Biotherapeutics | 42 mi |
| Multisite Implementation of COMPRENDO | N/A | University of California, San Diego | 42 mi |
| A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia | Phase 1/2 | Therapeutic Advances in Childhood Leukemia Consortium | 42 mi |
| A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) | Phase 3 | Merck Sharp & Dohme LLC | 42 mi |
| Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | Kura Oncology, Inc. | 42 mi |
| QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer | — | Abramson Cancer Center at Penn Medicine | 42 mi |
| Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis | Phase 3 | Immunovant Sciences GmbH | 42 mi |
| Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations | Phase 3 | Boehringer Ingelheim | 42 mi |
| A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa | — | argenx | 42 mi |
| PSMA PET Combined With MRI for the Detection of PCa | Phase 3 | Telix Pharmaceuticals (Innovations) Pty Limited | 42 mi |
| Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma | N/A | University of California, San Francisco | 42 mi |
| A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors | Phase 1 | Exelixis | 42 mi |
| Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma | Phase 1 | C. Babis Andreadis | 42 mi |
| Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer | Phase 2 | Faeth Therapeutics | 42 mi |
| Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors | Phase 1/2 | Robert Bok, MD, PhD | 42 mi |
| A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | 42 mi |
| ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma | Phase 1/2 | Eureka Therapeutics Inc. | 42 mi |
| A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) | Phase 3 | Bayer | 42 mi |
| A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis. | Phase 1/2 | Alexion Pharmaceuticals, Inc. | 42 mi |
| Biomarkers for Risk Stratification in Lung Cancer | — | University of California, San Francisco | 42 mi |
| Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma | Phase 2 | Allison O'Neill, MD | 42 mi |
| A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations | Phase 2 | Sameek Roychowdhury | 42 mi |
| Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC) | Phase 1/2 | University of California, San Francisco | 42 mi |
| Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations | Phase 3 | ArriVent BioPharma, Inc. | 42 mi |
| KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01) | — | Merck Sharp & Dohme LLC | 42 mi |
| Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management | — | M.D. Anderson Cancer Center | 42 mi |
| TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd | Phase 2 | Ana C Garrido-Castro, MD | 42 mi |
| Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma | Phase 1 | Charlie Wang, MD, PhD | 42 mi |
| Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial | Phase 2 | Massachusetts General Hospital | 42 mi |
| A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Genentech, Inc. | 42 mi |
| Imaging of Solid Tumors Using FAP-2286 | Phase 1 | Thomas Hope | 42 mi |
| Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers | Phase 2 | Memorial Sloan Kettering Cancer Center | 42 mi |
| Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL | Phase 2 | Allogene Therapeutics | 42 mi |
| Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults | Phase 2 | Sabine Mueller, MD, PhD | 42 mi |
| STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas | Phase 1/2 | STORM Therapeutics LTD | 42 mi |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) | Phase 2/3 | Bristol-Myers Squibb | 42 mi |
| A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer | Phase 1/2 | Genentech, Inc. | 42 mi |
| Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease | Phase 2 | University of Washington | 42 mi |
| A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 | Phase 2 | Seagen, a wholly owned subsidiary of Pfizer | 42 mi |
| Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors | Phase 1/2 | MBrace Therapeutics | 42 mi |
| A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer | Phase 2 | Puma Biotechnology, Inc. | 42 mi |
| A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors | Phase 1 | NiKang Therapeutics, Inc. | 42 mi |
| A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) | Phase 3 | Xynomic Pharmaceuticals, Inc. | 42 mi |
| ChangeGradients: Promoting Adolescent Health Behavior Change | N/A | University of California, San Francisco | 42 mi |
| A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors | Phase 1/2 | BioNTech SE | 42 mi |
| Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors | Phase 1/2 | MBrace Therapeutics | 42 mi |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer | Phase 1 | Cartography Biosciences | 42 mi |
| A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer | Phase 2 | John Sfakianos | 42 mi |
| The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections | — | Erasmus Medical Center | 42 mi |
| Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors | Phase 1 | Debiopharm International SA | 42 mi |
| Imaging of Solid Tumors Using 18F-TRX | Phase 1 | Rahul Aggarwal | 42 mi |
| JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC | Phase 3 | Johnson & Johnson Enterprise Innovation Inc. | 42 mi |
| A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% | Phase 3 | Bristol-Myers Squibb | 42 mi |
| Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies | Phase 1/2 | Georgiamune Inc | 42 mi |
| Patient Care Outreach, Navigation, Technology and Support 2.0 | N/A | University of California, San Francisco | 42 mi |
| Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies | Phase 1/2 | Institut de Recherches Internationales Servier | 42 mi |
| Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance | Phase 2 | University of California, San Francisco | 42 mi |
| Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer | Phase 1/2 | Vadim S Koshkin | 42 mi |
| Pan Tumor Rollover Study | Phase 2 | Bristol-Myers Squibb | 42 mi |
| Embryonal Tumor With Multilayered Rosettes | Phase 2 | University of California, San Francisco | 42 mi |
| A Study of Tarlatamab for People With Prostate Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | 42 mi |
| Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer | Phase 3 | Genmab | 42 mi |
| A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer | Phase 4 | Coherus Oncology, Inc. | 42 mi |
| Patient Decision-making About Precision Oncology in Veterans With Advanced Prostate Cancer | N/A | University of California, San Francisco | 42 mi |
| A Study of ZL-1310 in Participants With Selected Solid Tumors | Phase 1/2 | Zai Lab (Shanghai) Co., Ltd. | 42 mi |
| Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma | — | University of California, San Francisco | 42 mi |
| Combination Therapy for the Treatment of Diffuse Midline Gliomas | Phase 2 | University of California, San Francisco | 42 mi |
| Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma | Phase 2/3 | Daiichi Sankyo | 42 mi |
| Exercise and Movement to Enhance Resiliency in Cancer Patients | N/A | University of California, San Francisco | 42 mi |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | Phase 2 | QuantumLeap Healthcare Collaborative | 42 mi |
| A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy | Phase 3 | GlaxoSmithKline | 42 mi |
| Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE) | N/A | Breast Cancer Trials, Australia and New Zealand | 42 mi |
| Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer | Phase 1 | Washington University School of Medicine | 42 mi |
| A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 2 | Kyntra Bio | 42 mi |
| Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy | Phase 2 | David Oh | 42 mi |
| Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial | Phase 3 | University of California, San Francisco | 42 mi |
| Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03) | Phase 1/2 | Merck Sharp & Dohme LLC | 42 mi |
| BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001) | Phase 1/2 | Avenzo Therapeutics, Inc. | 42 mi |
| The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203) | — | Jasper Gerritsen | 42 mi |
| Effect of Ketamine on Intraoperative Motor Evoked Potentials | Phase 3 | University of California, San Francisco | 42 mi |
| Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer | Phase 2 | Robert Bok, MD, PhD | 42 mi |
| Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors | Phase 1/2 | Vivace Therapeutics, Inc | 42 mi |
| Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial | N/A | Dana-Farber Cancer Institute | 42 mi |
| Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma | — | University of California, San Francisco | 42 mi |
| Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells | Phase 1 | Hideho Okada, MD, PhD | 42 mi |
| Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. | Phase 3 | Iovance Biotherapeutics, Inc. | 42 mi |
| A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 3 | Janssen Research & Development, LLC | 42 mi |
| GOLD: Brief Intervention to Reduce Anxiety and Promote Resilience in Families of Youth With Cancer | N/A | Stanford University | 42 mi |
| Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation | Phase 1 | Institut de Recherches Internationales Servier | 42 mi |
| Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors | Phase 2 | National Cancer Institute (NCI) | 42 mi |
| Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma | Early 1 | New York Medical College | 42 mi |
| Predicting BCG Response | — | Cedars-Sinai Medical Center | 42 mi |
| A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) | Phase 3 | Merck Sharp & Dohme LLC | 42 mi |
| Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant | Phase 1/2 | SNIPR Biome Aps. | 42 mi |
| A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment | Phase 2 | Cedars-Sinai Medical Center | 42 mi |
| Pancreatic Cancer Early Detection Consortium | — | Arbor Research Collaborative for Health | 42 mi |
| Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia | Phase 1/2 | Disc Medicine, Inc | 42 mi |
| A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors | Phase 1/2 | Day One Biopharmaceuticals, Inc. | 42 mi |
| RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis | Phase 1/2 | Cabaletta Bio | 42 mi |
| The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201) | — | Jasper Gerritsen | 42 mi |
| Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma | Phase 2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 42 mi |
| The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302) | — | Jasper Gerritsen | 42 mi |
| Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors | Phase 1 | SystImmune Inc. | 42 mi |
| Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma | Phase 2 | University of California, San Francisco | 42 mi |
| Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | Phase 3 | PedAL BCU, LLC | 42 mi |
| Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | Phase 1/2 | IDEAYA Biosciences | 42 mi |
| Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 2 | SWOG Cancer Research Network | 42 mi |
| Enzalutamide Implants (Enolen) in Patients With Prostate Cancer | Phase 1 | Alessa Therapeutics Inc. | 42 mi |
| A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors | Phase 1/2 | Frontier Medicines Corporation | 42 mi |
| A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors | Phase 1/2 | Crinetics Pharmaceuticals Inc. | 42 mi |
| Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | Phase 3 | Gilead Sciences | 42 mi |
| A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer | Phase 3 | Daiichi Sankyo | 42 mi |
| Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer | Phase 1/2 | University of California, San Francisco | 42 mi |
| BBO-11818 in Adult Subjects With KRAS Mutant Cancer | Phase 1 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | 42 mi |
| International Rare Brain Tumor Registry | — | Children's National Research Institute | 42 mi |
| Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers | — | AIDS Malignancy Consortium | 42 mi |
| A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract | Phase 3 | Eli Lilly and Company | 42 mi |
| A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | Phase 1 | Nurix Therapeutics, Inc. | 42 mi |
| Prescription of Letrozole for Uterine Myoma | Phase 4 | University of California, San Francisco | 42 mi |
| Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | Phase 2/3 | Mirati Therapeutics Inc. | 42 mi |
| A Study of ZW251 in Participants With Advanced Solid Tumors | Phase 1 | Zymeworks BC Inc. | 42 mi |
| Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer | Phase 1 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | 42 mi |
| DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM) | Phase 2 | Diakonos Oncology Corporation | 42 mi |
| A Study of 177Lu-FAP-2286 in Advanced Solid Tumors | Phase 1/2 | Novartis Pharmaceuticals | 42 mi |
| Women Informed to Screen Depending on Measures of Risk (Wisdom Study) | N/A | University of California, San Francisco | 42 mi |
| Mirdametinib in Patients With Advanced NF1-mutant Melanoma | Phase 2 | Kevin Kim, MD | 42 mi |
| Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML | Phase 3 | Stichting Hemato-Oncologie voor Volwassenen Nederland | 42 mi |
| Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma | Phase 1 | Susan Chang | 42 mi |
| A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors | Phase 1/2 | Eikon Therapeutics | 42 mi |
| A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body | Phase 1/2 | Regeneron Pharmaceuticals | 42 mi |
| Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders | Phase 2 | Carl Allen | 42 mi |
| EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection | Phase 2 | New York Medical College | 42 mi |
| Comparison of Whole Body DWI to FDG PET | N/A | University of California, San Francisco | 42 mi |
| A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) | Phase 3 | Celgene | 42 mi |
| A Multicenter Cancer Biospecimen Collection Study | — | Cofactor Genomics, Inc. | 42 mi |
| Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer | Phase 2 | University of Washington | 42 mi |
| COMPASS Study for Metastatic Castration-resistant Prostate Cancer | — | Duke University | 42 mi |
| Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors | Phase 1 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | 42 mi |
| Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021) | Phase 1 | University of California, San Francisco | 42 mi |
| Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer | — | University of California, San Francisco | 42 mi |
| Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | Phase 1 | Inhibrx Biosciences, Inc | 42 mi |
| A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | Phase 3 | Vor Biopharma | 42 mi |
| Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma | Phase 2 | Varun Monga, MBBS | 42 mi |
| NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial | Phase 2 | New Approaches to Neuroblastoma Therapy Consortium | 42 mi |
| Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma | Phase 2 | Mary Feng, MD | 42 mi |
| A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM | Phase 1 | Boston Scientific Corporation | 42 mi |
| CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma | Phase 1/2 | Children's Oncology Group | 42 mi |
| ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors | Phase 1 | Sabine Mueller, MD, PhD | 42 mi |
| A Study of MGC028 in Participants With Advanced Solid Tumors | Phase 1 | MacroGenics | 42 mi |
| A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | Phase 2 | VA Office of Research and Development | 42 mi |
| Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors | Phase 1/2 | Georgiamune Inc | 42 mi |
| A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. | Phase 2 | AbbVie | 42 mi |
| Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma | Phase 1 | Robert Flavell, MD, PhD | 42 mi |
| The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202) | — | Jasper Gerritsen | 42 mi |
| Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer | N/A | University of California, San Francisco | 42 mi |
| Precision-Based Genomics in Prostate Cancer | — | National Cancer Institute (NCI) | 42 mi |
| Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer | — | University of California, San Francisco | 42 mi |
| PROmOting Gynecologic Cancer Patients With Frailty to Achieve Functional Recovery | — | University of California, San Francisco | 42 mi |
| Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer | Phase 2 | University of California, San Francisco | 42 mi |
| Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer | Phase 3 | Olema Pharmaceuticals, Inc. | 42 mi |
| Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors | Phase 1/2 | Ensem Therapeutics | 42 mi |
| Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms | Phase 1/2 | University of California, San Francisco | 42 mi |
| A Beta-only IL-2 ImmunoTherapY Study | Phase 1/2 | Medicenna Therapeutics, Inc. | 42 mi |
| Feasibility of HPV Testing With Mail-delivered Sample Collection Kits | — | University of California, San Francisco | 42 mi |
| A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors | Phase 1 | Nested Therapeutics, Inc | 42 mi |
| Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors | Phase 1 | MOMA Therapeutics | 42 mi |
| Wearable Activity Tracking to Curb Hospitalizations | — | University of California, San Francisco | 42 mi |
| Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer | Phase 1 | Amgen | 42 mi |
| Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE) | Phase 2 | Children's Hospital of Philadelphia | 42 mi |
| A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma | Phase 1/2 | ModernaTX, Inc. | 42 mi |
| Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer | Phase 2 | Thomas Hope | 42 mi |
| Two-fraction HDR Monotherapy for Localized Prostate Cancer | N/A | University of California, San Francisco | 42 mi |
| A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) | Phase 1/2 | Merck Sharp & Dohme LLC | 42 mi |
| A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel | Phase 2 | Janssen Research & Development, LLC | 42 mi |
| PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors | Phase 1/2 | Theodore Laetsch | 42 mi |
| A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial | Phase 2 | Duke University | 42 mi |
| Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors | Phase 1/2 | Aminex Therapeutics, Inc. | 42 mi |
| Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas | Phase 1 | Children's Hospital of Philadelphia | 42 mi |
| Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms | — | University of California, San Francisco | 42 mi |
| NEO100 and High-Grade Meningioma | Phase 2 | Neonc Technologies, Inc. | 42 mi |
| Combination Therapy in Cancers With Mutations in DNA Repair Genes | Phase 1 | University of California, San Francisco | 42 mi |
| Clinical Outcomes of the Endoscopic Resection of Premalignant and Malignant Gastrointestinal Lesions | — | California Pacific Medical Center Research Institute | 42 mi |
| A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer | Phase 1/2 | Alliance Foundation Trials, LLC. | 42 mi |
| A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events | Phase 2 | Janssen Research & Development, LLC | 42 mi |
| Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL | Phase 2 | Etan Orgel | 42 mi |
| Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr | N/A | Weill Medical College of Cornell University | 42 mi |
| A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer | Phase 3 | Verastem, Inc. | 42 mi |
| KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04) | Phase 1/2 | Merck Sharp & Dohme LLC | 42 mi |
| KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) | Phase 1/2 | Merck Sharp & Dohme LLC | 42 mi |
| A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy | Phase 1 | Children's Oncology Group | 42 mi |
| A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) | Phase 3 | Regeneron Pharmaceuticals | 42 mi |
| Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) | Phase 1 | Janux Therapeutics | 42 mi |
| Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) | Phase 2 | Dana-Farber Cancer Institute | 42 mi |
| Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617 | Phase 1 | Thomas Hope | 42 mi |
| Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | Phase 1/2 | ModernaTX, Inc. | 42 mi |
| Study of PF-07248144 in Advanced or Metastatic Solid Tumors | Phase 2 | Pfizer | 42 mi |
| Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry) | — | University of California, San Francisco | 42 mi |
| Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer | Phase 1 | Amgen | 42 mi |
| Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies | Phase 1/2 | AstraZeneca | 42 mi |
| Targeted Therapy to Increase RAI Uptake in Metastatic DTC | — | Children's Hospital of Philadelphia | 42 mi |
| Microbiome and Association With Implant Infections | Phase 2 | University of California, San Francisco | 42 mi |
| The Ailliance Post-Market Clinical Study | N/A | Medtronic Spinal and Biologics | 42 mi |
| A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma | Phase 2 | Janssen Research & Development, LLC | 42 mi |
| LYL273 for Patients With Relapsed or Refractory mCRC | Phase 1/2 | Lyell Immunopharma, Inc. | 42 mi |
| Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL | Phase 2 | Hoffmann-La Roche | 42 mi |
| Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma | Phase 2 | University of California, San Francisco | 42 mi |
| Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma | Phase 3 | Revolution Medicines, Inc. | 42 mi |
| Prospective Registry of Histotripsy for Soft Tissue Tumors | — | University of California, San Francisco | 42 mi |
| 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer | Phase 1 | University of California, San Francisco | 42 mi |
| Venetoclax Basket Trial for High Risk Hematologic Malignancies | Phase 1 | Andrew E. Place, MD | 42 mi |
| A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC | Phase 1/2 | TRIANA Biomedicines, Inc. | 42 mi |
| A Study of TAK-505 in Adults With Solid Tumors | Phase 1/2 | Takeda | 42 mi |
| Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM | Phase 3 | CarThera | 42 mi |
| Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML) | Phase 3 | Stichting Hemato-Oncologie voor Volwassenen Nederland | 42 mi |
| A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma | Phase 3 | Incyte Corporation | 42 mi |
| Feasibility Study of Suizenji, in Patients With Unresectable Pancreatic Ductal Adenocarcinoma (SUNRISE-II) | Early 1 | SONIRE Therapeutics Inc. | 42 mi |
| A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A) | Phase 1/2 | Merck Sharp & Dohme LLC | 42 mi |
| Efficacy of Laser Interstitial Thermal Therapy in Young Persons With Low-grade Glioma | N/A | University of California, San Francisco | 42 mi |
| Novel Body Composition Measurements in Association With Outcomes of Breast Reconstruction Reconstruction | — | University of California, San Francisco | 42 mi |
| A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs | Phase 1/2 | AstraZeneca | 42 mi |
| AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01) | Phase 3 | AstraZeneca | 42 mi |
| Intratumoral N17350 in Advanced Solid Tumors | Phase 1/2 | Onchilles Pharma Inc | 42 mi |
| Tumor Genomics, Individual Risk Factors, and External Drivers of Health on Health Outcomes for Patients With Meningioma | — | University of California, San Francisco | 42 mi |
| A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression | Phase 3 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 42 mi |
| Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers | — | ECOG-ACRIN Cancer Research Group | 42 mi |
| A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers | Phase 1 | Eli Lilly and Company | 42 mi |
| A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors | Phase 1 | Relay Therapeutics, Inc. | 42 mi |
| Magnetic Resonance Imaging in Radiotherapy for Breast Cancer | — | University of California, San Francisco | 42 mi |
| (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors | Phase 3 | Cogent Biosciences, Inc. | 42 mi |
| Social, Structural, and Lifestyle Drivers of Prostate Cancer Disparities | — | University of California, San Francisco | 42 mi |
| A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation | Phase 3 | Astellas Pharma Global Development, Inc. | 42 mi |
| Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT) | Phase 2 | Sabine Mueller, MD, PhD | 42 mi |
| ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer | Phase 2 | Laura Huppert, MD, BA | 42 mi |
| Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases | Phase 2 | Kelly Fitzgerald, MD | 42 mi |
| A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) | Phase 2 | Bristol-Myers Squibb | 42 mi |
| DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy | Phase 3 | Boehringer Ingelheim | 42 mi |
| A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma | Phase 2 | Jazz Pharmaceuticals | 42 mi |
| An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC | Phase 3 | AstraZeneca | 42 mi |
| Liver Transplantation From Donors With HIV: Impact on Opportunistic Infections, Cancer, and Long-Term Outcomes (Expanding HOPE Liver) | N/A | Johns Hopkins University | 42 mi |
| Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease | Phase 1/2 | Sabine Mueller, MD, PhD | 42 mi |
| ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma | Phase 2 | Michael Spinner, MD | 42 mi |
| A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors | Phase 1 | Pierre Fabre Medicament | 42 mi |
| CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial | Phase 2 | University of California, San Francisco | 42 mi |
| Assessing Brain Metabolism Using MRS With Deuterated Glucose | — | University of California, San Francisco | 42 mi |
| Delayed Toxicities Post-CAR-T | — | Icahn School of Medicine at Mount Sinai | 42 mi |
| Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | Phase 1 | AbbVie | 42 mi |
| Generative AI Patient Education Module for Breast Oncology | N/A | University of California, San Francisco | 42 mi |
| Evaluating the Impact of CONNECT in a Multilingual Population | N/A | University of California, San Francisco | 42 mi |
| A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma | Phase 3 | Hoffmann-La Roche | 43 mi |
| A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) | Phase 3 | Merck Sharp & Dohme LLC | 43 mi |
| Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL | Phase 2 | AstraZeneca | 43 mi |
| Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer | Phase 2/3 | BioNTech SE | 45 mi |
| Molecular Genetics Studies of Cancer Patients and Their Relatives | — | City of Hope Medical Center | 45 mi |
| Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer | Phase 3 | National Cancer Institute (NCI) | 47 mi |
| Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy | Phase 3 | SWOG Cancer Research Network | 49 mi |